1. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents.
- Author
-
Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, and Dubreuil LJ
- Subjects
- Bacteria, Anaerobic enzymology, Bacterial Infections drug therapy, Carbon Dioxide metabolism, Drug Resistance, Bacterial, Europe epidemiology, Humans, Microbial Sensitivity Tests, Quality Control, United States epidemiology, beta-Lactamases metabolism, Amoxicillin-Potassium Clavulanate Combination pharmacology, Anti-Infective Agents pharmacology, Bacteria, Anaerobic drug effects, Bacterial Infections epidemiology, Bacterial Infections microbiology, Drug Therapy, Combination pharmacology, Population Surveillance
- Abstract
In vitro susceptibility data were collected for co-amoxiclav and other antimicrobial agents against 1297 recent anaerobe isolates collected in Europe and the USA. The co-amoxiclav (amoxicillin/clavulanic acid) MIC(50/90)s (amoxicillin/clavulanic acid concentration in a ratio of 2:1, expressed in terms of amoxicillin concentration in mg/L) were 0.5/4 for Bacteroides fragilis, 96% susceptible) except E. corrodens (MIC(50/90) of >32/>64 mg/L), which is a capnophilic organism. Imipenem was also highly active against all species (>98% susceptible). Levofloxacin and clindamycin were the least potent agents tested, particularly against Bacteroides, Prevotella and Peptostreptococcus (levofloxacin susceptibility rates: Bacteroides 72.7%, Prevotella 71.5%, F. magna 72.4%; clindamycin susceptibility rates: Bacteroides 79.5%, Prevotella 92.1%, F. magna 84.7%).
- Published
- 2004
- Full Text
- View/download PDF